Cargando…
Bi-anti therapy for SARS-CoV-2 infection among mild/moderate patients to prevent coronavirus disease 2019 from progressing to severe disease
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900530/ https://www.ncbi.nlm.nih.gov/pubmed/36747253 http://dx.doi.org/10.1186/s12967-023-03965-3 |
| _version_ | 1784882866836996096 |
|---|---|
| author | Xu, Jian |
| author_facet | Xu, Jian |
| author_sort | Xu, Jian |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9900530 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99005302023-02-06 Bi-anti therapy for SARS-CoV-2 infection among mild/moderate patients to prevent coronavirus disease 2019 from progressing to severe disease Xu, Jian J Transl Med Letter to the Editor BioMed Central 2023-02-06 /pmc/articles/PMC9900530/ /pubmed/36747253 http://dx.doi.org/10.1186/s12967-023-03965-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Letter to the Editor Xu, Jian Bi-anti therapy for SARS-CoV-2 infection among mild/moderate patients to prevent coronavirus disease 2019 from progressing to severe disease |
| title | Bi-anti therapy for SARS-CoV-2 infection among mild/moderate patients to prevent coronavirus disease 2019 from progressing to severe disease |
| title_full | Bi-anti therapy for SARS-CoV-2 infection among mild/moderate patients to prevent coronavirus disease 2019 from progressing to severe disease |
| title_fullStr | Bi-anti therapy for SARS-CoV-2 infection among mild/moderate patients to prevent coronavirus disease 2019 from progressing to severe disease |
| title_full_unstemmed | Bi-anti therapy for SARS-CoV-2 infection among mild/moderate patients to prevent coronavirus disease 2019 from progressing to severe disease |
| title_short | Bi-anti therapy for SARS-CoV-2 infection among mild/moderate patients to prevent coronavirus disease 2019 from progressing to severe disease |
| title_sort | bi-anti therapy for sars-cov-2 infection among mild/moderate patients to prevent coronavirus disease 2019 from progressing to severe disease |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900530/ https://www.ncbi.nlm.nih.gov/pubmed/36747253 http://dx.doi.org/10.1186/s12967-023-03965-3 |
| work_keys_str_mv | AT xujian biantitherapyforsarscov2infectionamongmildmoderatepatientstopreventcoronavirusdisease2019fromprogressingtoseveredisease |